Aurobindo Pharma’s Q1 FY26 results were like a bittersweet pill: revenue climbed 4% YoY to ₹7,868 cr, but profit fell 10% to ₹824 cr. Margins stayed around 20%, and management bragged about 14 USFDA ANDA approvals. To sweeten the bitterness, they announced a 400% interim dividend (₹4/share). Investors cheered; auditors smirked.
2. Introduction
India’s No. 2 pharma exporter and US generics giant, Aurobindo Pharma, continues to straddle multiple geographies with APIs and formulations. While ANDA approvals keep the growth pipeline alive, pricing pressure in the US and currency swings dented margins. Q1 FY26 numbers show a solid top line but declining profitability. The dividend bonanza signals confidence—or maybe just a distraction.
3. Business Model (WTF Do They Even Do?)
Aurobindo is in:
APIs (active pharmaceutical ingredients)
Generic Formulations (oral solids, injectables)
US Generics (largest revenue contributor)
Europe & ROW (top-10 generic presence in 8 countries)
Revenue heavily skewed to US generics. Competitive pricing, regulatory hurdles, and product launches dictate fortunes. High capex and R&D spend keep them in the game.
4. Financials Overview
Revenue (Q1 FY26): ₹7,868 cr (↑3.98% YoY)
EBITDA: ₹1,603 cr (margin 20%)
PAT: ₹824 cr (↓10% YoY)
EPS (Q1): ₹14.08
ROE (FY25): 11.2%
ROCE (FY25): 14.3%
Commentary: Revenue steady, margins healthy, but profits shrank due to higher interest and depreciation. Growth muted vs peers like Sun Pharma or Cipla.
5. Valuation
a) P/E Method
EPS TTM ₹57.9, CMP ₹1,090 → P/E ~18.8x. Peer P/E: Sun Pharma 34x, Cipla 23x, Dr Reddy’s 18x. Fair Value (P/E 16–20x) → ₹926–₹1,158.
